ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.00
0.00%
US Tech 100
19,908.00
0.04%
S&P 500
5,859.85
0.00%
US Dollar vs CAD
1.38194
0.12%
Bitcoin
65,702.32
-0.53%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX

  6. Satellos Bioscience Inc (MSCL) Share Price

Satellos Bioscience Inc

Satellos Bioscience Inc (MSCL)

Satellos Bioscience Inc
0.64
0.00
(0.00%)
Closed October 15 3:12PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.64
Bid
0.64
Ask
0.66
Volume
-
0.00 Day's Range 0.00
0.38 52 Week Range 0.80
Market Cap
72.187M
Previous Close
0.64
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
78,555
Shares Outstanding
112,792,000
Dividend Yield
-
PE Ratio
-4.54
Earnings Per Share (EPS)
-0.14
Revenue
-
Net Profit
-15.89M

About Satellos Bioscience Inc

Sector
Coml Physical, Biologcl Resh
Industry
Pharmaceutical Preparations
Website
www.satellos.com
Headquarters
Toronto, Ontario, Can
Founded
2007
Satellos Bioscience Inc is listed in the Coml Physical, Biologcl Resh sector of the Toronto Stock Exchange with ticker MSCL. The last closing price for Satellos Bioscience was $0.64. Over the last year, Satellos Bioscience shares have traded in a share price range of $ 0.38 to $ 0.80.

Satellos Bioscience currently has 112,792,000 shares outstanding. The market capitalization of Satellos Bioscience is $72.19 million. Satellos Bioscience has a price to earnings ratio (PE ratio) of -4.54.

Ask ADVFN Intelligence (AI)

MSCL Latest News

More News

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf - No adverse events and no significant...

October 01 2024
Business Wire

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in Q4 2024 - Initiation of the second component of...

September 18 2024
Business Wire

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

September 05 2024
Business Wire

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech...

August 19 2024
Business Wire

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

- Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at four-month point - Receipt of Orphan Drug and...

August 12 2024
Business Wire

Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

– SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) – DMD is a...

August 08 2024
Business Wire

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience...

July 11 2024
Business Wire

Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)

–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to...

July 02 2024
Business Wire

Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference

– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX:...

June 27 2024
Business Wire

Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy

Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD...

May 28 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0610.34482758620.580.70.573706240.60083637CS
40.1530.6122448980.490.70.451230820.5641644CS
120.1325.49019607840.510.70.45785550.53364825CS
260.1325.49019607840.510.70.38651110.52075497CS
520.023.225806451610.620.80.38690020.53977307CS
1560.023.225806451610.620.80.38690020.53977307CS
2600.023.225806451610.620.80.38690020.53977307CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0

Discussion

View Full Feed
threewheeler threewheeler 4 minutes ago
GRLT Nice changes Mr. Zhang officially CEO of GRLT Change of Control

https://www.otcmarkets.com/stock/GRLT/profile more updates expected anytime now
GRLT
Moon Bot Moon Bot 5 minutes ago
Very sune
ILAL
Golden Cross Golden Cross 5 minutes ago
$AGBA Conor McGregor is part a owner in the Bare Knuckle Fighting Championship, (BKFC). Triller is the majority owner of #BKFC
https://youtube.com/watch?v=csJvgs7XeMs……
AGBA
jay_tee jay_tee 5 minutes ago
Never saw FOXO on any major or minor list of up and coming AI opportunities. But hey if any profit eventually trickles down to Rnva, I’m all for it.
FOXO
befast befast 5 minutes ago
Down to 0.3 already. Will sell at the opening and buy back tonight
DBGI
infamous infamous 5 minutes ago
SOFI is over 10 now. who was the knucklehead who kept saying this will NEVER get to 10 again and this would be under 1.00 by now? can someone here remind me who that was? thanx
SOFI
frrol frrol 5 minutes ago
Annovis's Maccecchini is another example of a promotional biotech manager with credibility issues. This is why biotech can really be dangerous for the foolish. The drug may have clinical value but you don't rely on the company to tell you that.

https://www.annovisbio.com/press-release
AVXL
chazzy1 chazzy1 6 minutes ago
I would like to thank InvestorinAZ for clearing up one misunderstanding that I had concerning the recent dismissals without prejudice of the two cases involving T-Mobile and Verizon. I had erroneously assumed that those were the same cases that were awaiting a response from Judge Albright to a motio
VPLM
Tahoe2468 Tahoe2468 6 minutes ago
NEWS!!! Oh boy oh boy

Ronn Announces NYC Visit to Sign Joint Venture Agreement with Hydrogen Energy Systems
Tuesday, 15 October 2024 08:15 AM
ACCESSWIRE | Article Logo
RONN
Share this Article
Share on Twitter
Share on Facebook
Share on
RONN
hawk2421 hawk2421 6 minutes ago
Interesting and confusing patent update. Looks like a patent got issued by Rittman on 10/3 with the applicant being Vision Wave. It looks to be the same patent granted in June with the applicant Tokenize.

https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/20240331194?
GTCH
resx18 resx18 6 minutes ago
$CBDL Announces Strategic MOU With U.S. Armed Forces for Groundbreaking Mushroom Supplement
https://finance.yahoo.com/news/cbd-life-sciences-inc-cbdl-120000954.html
CBDL
resx18 resx18 6 minutes ago
$CBDL Announces Strategic MOU With U.S. Armed Forces for Groundbreaking Mushroom Supplement
https://finance.yahoo.com/news/cbd-life-sciences-inc-cbdl-120000954.html
CBDL
Think1st Think1st 6 minutes ago
https://www.nationaldaycalendar.com/national-day/national-grouch-day-october-15
LWLG
TJG TJG 6 minutes ago
This will give some an idea of the extent of where OneMindNG is and what they are involved in . This is from OneMindNG web site meet:
Jorge Luengo Azcona,
OneMindNG
Head of Sales Middle East and APAC

OneMind TechnologiesOneMind Technologies
Aug 2022 - Pres
AFFU
JNdouble1 JNdouble1 7 minutes ago
“Seems to me like a lot of stuff goes on behind the scenes that none of us know about. ”

Indeed, everything goes on behind the scenes and investors know nothing about any of it.

BIEL is completely uncommunicative. Your example here is exactly the kind of thing they cou
BIEL
BullNBear52 BullNBear52 7 minutes ago
Yes. Picked up 100 shares when it tanked previously for my son's account for a long time hold. I need to find a Fidelity fund to buy for him as I'm running out of stocks to buy. I'm still thinking about NKE and NU.
NKE
Konaploinks Konaploinks 7 minutes ago
In a few years? nope Like I said before. Future predictions will be taken out faster and faster now as these 64 Qbit machines are daisy chained together
and compute faster and faster and faster solving very complex problems to move quantum ever forward into a new dimension. A parallel unive
IONQ
OldAIMGuy OldAIMGuy 8 minutes ago
Hi MD,
There's a big SCHW uptick in the Pre-Market this AM. It's up 9+% as of this time.

That makes me smile.

Best wishes,
OAG
SCHW
gp22 gp22 8 minutes ago
$RCAT: Drone red hot. Partner $PDYN @ $2.40s: AI software for ANY robot. Cars, drones, industrial, military, etc. Has $25M cash & 1/4 the float of $RCAT.
$PDYN AI software are now in $RCAT drones.
Load up on $PDYN while it is under $6.00
$PDYN & $RCAT news:
https://www.b
PDYN RCAT
VOIP20 VOIP20 8 minutes ago
The latest quarterly report should be dropping soon. Could be any day now. Then we will see the Sri Lanka results. Who among us is expecting much of a change?
VPER
BIOChecker4 BIOChecker4 8 minutes ago
Such a clever retort!
AVXL
gp22 gp22 8 minutes ago
$RCAT: Drone red hot. Partner $PDYN @ $2.40s: AI software for ANY robot. Cars, drones, industrial, military, etc. Has $25M cash & 1/4 the float of $RCAT.
$PDYN AI software are now in $RCAT drones.
Load up on $PDYN while it is under $6.00
$PDYN & $RCAT news:
https://www.b
PDYN RCAT
steel8000 steel8000 8 minutes ago
If the d steal the election this is in the toilet
TGLO
resx18 resx18 8 minutes ago
Good Morning $CBDW
CBDW
PioneerPhoenix73 PioneerPhoenix73 8 minutes ago
First, the door thing. You think a tiny bump into a sign would jam a Tesla door shut? Have you ever seen one? They're practically magic portals that open with a wave of your foot. More likely, the driver was auditioning for a superhero landing and forgot the whole "sticking the landing" part.
TSLA

Your Recent History

TSX
MSCL
Satellos Bioscience
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved